SUBSCRIBE
SUBSCRIBE

Mini Antibodies: Biotech’s Next Big Thing?

September 12, 2008 | 
1 min read

LONDON (Reuters) - GlaxoSmithKline Plc’s head of biotech research is excited about a new generation of “slimline” antibody medicines that may be successors to current blockbusters such as Avastin and Rituxan.

Europe
MORE ON THIS TOPIC
3d illustration of a black dragon flying on an extraterrestrial world with mountains beneath.
Neuropsychiatric disorders
Draig Takes Flight With $140M Series A To Advance Neuropsych Drugs
June 18, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: European flags flap in the wind outside
Opinion
US Uncertainty Creates Clinical Trial Leadership Opportunity for Europe
June 16, 2025
 · 
6 min read
 · 
Craig Koch
Illustration showing large scissors cutting employees in half
Layoffs
The 5 Largest Biopharma Layoffs of Q1 2025: Updated
May 13, 2025
 · 
5 min read
 · 
Angela Gabriel
European Union flags in front of the blurred European Parliament in Brussels, Belgium
Europe
With Tariffs Looming, EU and US Pharmas Make Demands of European Commission
April 16, 2025
 · 
2 min read
 · 
Tristan Manalac